Medical treatment implementation in ambulatory patients with HF: preliminary data from the nationwide BRING–UP3 HF study
Abstract
Current ESC guidelines introduced a four–pillar approach for the treatment of HFrEF, and a Class IA recommendation for Empagliflozin and Dapagliflozin in HfmrEF and HFpEF.
BRING–UP–3 Heart Failure (HF) study was designed to guide the guideline implementation recommendations in HF patients enrolled by a large sample of Italian cardiology sites.
BRING–UP–3 HF study is an observational, prospective, nationwide investigation encompassing 179 sites enrolling ambulatory and hospitalized HF patients. The study includes an educational intervention followed by two three–month enrollment periods and by a six–month follow–up period with end–point evaluation. For HFrEF patients, the objective is to describe the proportion of patients who receive the four pillars. Here we present the baseline data of the ambulatory cohort.
A total of 3,830 ambulatory patients were included in the study. The mean age was 70±12 years (34.5% over 75 years), females were 21.9%. The most prevalent group was HFrEF (58.4%), followed by HFimpEF (17.4%), HFmrEF (14.4%), and HFpEF (9.8%). Hypertension, atrial fibrillation, diabetes mellitus, and chronic kidney disease were reported in 68.2%, 40.4%, 31.0%, and 33.1%, respectively. Figure 1 reports pre–post visit prescription rates of main HF medical treatments among different groups according to ejection fraction phenotypes. beta–blockers and RASi (with ARNIs widely preferred over ACE–I/ARNIs ) were prescribed in over 90% while SGLT2i and MRAs were prescribed in…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 3,830 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.